[go: up one dir, main page]

MA54601A - Nouvelles protéines de liaison multi-spécifiques à base de pseudofab - Google Patents

Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Info

Publication number
MA54601A
MA54601A MA054601A MA54601A MA54601A MA 54601 A MA54601 A MA 54601A MA 054601 A MA054601 A MA 054601A MA 54601 A MA54601 A MA 54601A MA 54601 A MA54601 A MA 54601A
Authority
MA
Morocco
Prior art keywords
pseudofab
new
specific binding
binding proteins
based multi
Prior art date
Application number
MA054601A
Other languages
English (en)
Inventor
Christian Beil
Karl-Christian Engel
Gerhard Hessler
Soraya Hoelper
Christian Lange
Thomas Langer
Cendrine Lemoine
Wulf-Dirk Leuschner
Bruederle Sevim Oezguer
Ercole Rao
Nadja Spindler
Sandra Weil
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18306840.2A external-priority patent/EP3674319A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA54601A publication Critical patent/MA54601A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054601A 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab MA54601A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306840.2A EP3674319A1 (fr) 2018-12-24 2018-12-24 Protéines de liaison multispécifiques à base de pseudofab
EP19305813 2019-06-21

Publications (1)

Publication Number Publication Date
MA54601A true MA54601A (fr) 2022-03-30

Family

ID=69174547

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054601A MA54601A (fr) 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Country Status (16)

Country Link
US (2) US11739160B2 (fr)
EP (1) EP3902825A1 (fr)
JP (1) JP7734075B2 (fr)
KR (1) KR20220015369A (fr)
CN (1) CN114885609A (fr)
AU (1) AU2019416895A1 (fr)
BR (1) BR112021012337A2 (fr)
CA (1) CA3124770A1 (fr)
CO (1) CO2021009025A2 (fr)
IL (2) IL284317B2 (fr)
MA (1) MA54601A (fr)
MX (1) MX2021007677A (fr)
PH (1) PH12021500028A1 (fr)
SG (1) SG11202106393SA (fr)
TW (1) TW202041534A (fr)
WO (1) WO2020136564A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54601A (fr) 2018-12-24 2022-03-30 Sanofi Sa Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2024206669A2 (fr) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Anticorps pour cibler cd47 et b7h3 et leurs méthodes d'utilisation
US20250388676A1 (en) * 2024-06-20 2025-12-25 Sanofi Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5732168A (en) 1995-10-31 1998-03-24 Hewlett Packard Company Thermal optical switches for light
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
CA2410551A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Proteines de fusion heterodimeres
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP2008523083A (ja) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
CA2646965C (fr) 2006-03-24 2016-06-21 Jonathan H. Davis Domaines de proteine heterodimerique d'ingenierie
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US20120009182A1 (en) 2008-12-23 2012-01-12 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
PL2522724T3 (pl) 2009-12-25 2020-07-13 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2569337A1 (fr) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Protéines hétérodimériques et leurs procédés de production et de purification
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
PT2825559T (pt) 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
WO2014004586A1 (fr) 2012-06-25 2014-01-03 Zymeworks Inc. Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
HK1215950A1 (zh) 2012-09-25 2016-09-30 艾科诺斯科技股份有限公司 异源二聚免疫球蛋白的纯化
CN104903352A (zh) 2012-12-28 2015-09-09 艾伯维公司 多价结合蛋白组合物
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015033223A2 (fr) 2013-09-03 2015-03-12 Novimmune S.A. Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées
RU2016144176A (ru) * 2014-04-11 2018-05-14 МЕДИММЬЮН, ЭлЭлСи Биспецифические антитела к her2
US10392438B2 (en) * 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
EP3155018A4 (fr) 2014-06-06 2018-01-10 The California Institute for Biomedical Research Protéines de fusion à anticorps à région constante et compositions les contenant
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
ES2764111T3 (es) * 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
WO2016146594A1 (fr) 2015-03-13 2016-09-22 Novimmune Sa Procédés de purification d'anticorps bispécifiques
WO2017005649A1 (fr) 2015-07-09 2017-01-12 Genmab A/S Anticorps bispécifiques et multispécifiques et procédé pour l'isolement de ceux-ci
JP7195929B2 (ja) 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
PH12020550112A1 (en) * 2017-09-22 2020-10-26 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
MA54601A (fr) 2018-12-24 2022-03-30 Sanofi Sa Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
EP3674319A1 (fr) 2018-12-24 2020-07-01 Sanofi Protéines de liaison multispécifiques à base de pseudofab
US20230103563A1 (en) * 2020-03-30 2023-04-06 Sanofi Split ch2 domains
CN116964084A (zh) * 2021-02-07 2023-10-27 正大天晴药业集团股份有限公司 双特异性抗体

Also Published As

Publication number Publication date
IL284317A (en) 2021-08-31
JP2024504880A (ja) 2024-02-02
AU2019416895A1 (en) 2021-08-12
TW202041534A (zh) 2020-11-16
US20230391888A1 (en) 2023-12-07
IL319262A (en) 2025-04-01
EP3902825A1 (fr) 2021-11-03
JP7734075B2 (ja) 2025-09-04
IL284317B2 (en) 2025-10-01
US20200255540A1 (en) 2020-08-13
CO2021009025A2 (es) 2021-12-10
US11739160B2 (en) 2023-08-29
KR20220015369A (ko) 2022-02-08
WO2020136564A1 (fr) 2020-07-02
MX2021007677A (es) 2021-12-10
SG11202106393SA (en) 2021-07-29
BR112021012337A2 (pt) 2021-09-14
PH12021500028A1 (en) 2022-05-02
CA3124770A1 (fr) 2020-07-02
AU2019416895A2 (en) 2021-09-09
CN114885609A (zh) 2022-08-09
IL284317B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
EP4225364A4 (fr) Protéines f hmpv stabilisées par préfusion
EP3655432A4 (fr) Protéines de liaison 1
EP3850007A4 (fr) Protéines bispécifiques modifiées
PT3649151T (pt) Proteínas de suporte
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3621994A4 (fr) Protéines de liaison à la mésothéline
EP3307266A4 (fr) Nouvelles polythérapies à base de cannabinoïdes pour le myélome multiple (mm)
MA50942A (fr) Protéines de liaison à l'adn modifiées
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
DK3784047T3 (da) Gærproteiner
EP3806645A4 (fr) Composition nutritionnelle à base de protéine de pois intacte
EP3917542A4 (fr) Protéines de liaison multispécifiques
IL290878A (en) Protein based cannabis compositions
MA54601A (fr) Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
EP3514167A4 (fr) Peptide de liaison à la thrombospondine 1
DK3737402T5 (da) Modificeret protein
EP3802565A4 (fr) Polypeptides
EP4159872C0 (fr) Marquage de l'adn
EP3612207C0 (fr) Polypeptides de coversine dépourvus de liaison c5
DK3840767T3 (da) Peptider
EP4022337C0 (fr) Détermination de position
EP3688037A4 (fr) Protéines de fusion immunomodulatrices
EP3848534A4 (fr) Machine à lier